InvestorsHub Logo
Followers 2
Posts 518
Boards Moderated 0
Alias Born 11/21/2022

Re: Fireman02360 post# 389430

Monday, 12/05/2022 5:27:19 PM

Monday, December 05, 2022 5:27:19 PM

Post# of 463360

$150 million in cash with little reason to dilute before revenue.



yeah that's if a large phase 3 isn't needed, which no one knows right now. A lot of the experts in the space have said it will be needed. I, as well as many others, have commented that we can easily see the fda being reluctant to hand out an advanced approval after they were reamed for approving that worthless Biogen drug.


Successful Alz Phase 3


Hopefully, but let's see the peer reviewed data in a few months to make sure

3-71 sitting in the "wings".


which would require more trials which means dilution. If retts and AD doesn't come through, the share price will plummet

Against all odds, Missling has bought this tiny little company from $100mil MC to just under $800 million and on the verge of becoming a BP. A bit more patience is all that is needed here. And despite what the nay-sayers are and have been saying, here we are.....at the crossroads of being a pre-commercial biotech to a very large one. Please make no mistake about it. I also suspect, within the next year, you will be the one touting just how great CEO Missling is and has been. Or, you will be wiped out with your short position. Thanks for the cheap shares today, Mr. Chomper. From the bottom of my heart, I truly do appreciate the work you try to do here. But the eye on the prize investors cannot be fooled. You know it, and so do we. Time is ticking, isnt it???



This is where this forum gets delusional. What has Missling does that's so novel / couldn't be replicated by another CEO? He has missed pretty much every single deadline he's ever given himself. He has repeatedly been caught off guard by short and distort and provides them cheap ammo with botched data readouts. He took profit when his shares had skyrocketed and then refuses to buy more when the prices are down over 50% from ath in the year his company has their biggest ever presentation. The science behind the company (which he didn't invent) is great, but to call Missling great is just inaccurate.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News